Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotic Concentration Monitoring in CF Sputum
NCT02840136Terminated
- Sponsor
- Ghent University
- Start
- Feb 2016
- Primary completion
- Sep 2017
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Open-label, single-arm trial of piperacillin + tazobactam, meropenem and ceftazidime in cystic fibrosis (CF), sponsored by Ghent University. Primary endpoints: Concentration changes induced by aerosol use at 2 hours, Antibiotic distribution in single sputum sample at 0 hours and 1 more. Started Feb 2016; status: terminated.
02
Drugs
piperacillin + tazobactammeropenemceftazidime
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02840136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02840136.